Sunday, October 8, 2017

Glass...

The cartoonist's homepage, pnj.com/opinion

Nothing much to talk about now a days. So here comes the next Hurricane. Days of continue pounding on what possibly will happen in the coming three days.

Nothing else can save us except a new election.

Saturday, October 7, 2017

Marketing..

Image result for pharmaceutical marketing and R&D
Shares of $17 billion drug stock Mylan NV (MYL) are in rally-mode , breaking out to nearly 19% gains on the heels of an FDA approval.
Mylan scored the FDA's blessing on its generic copy of Teva Pharmaceutical's (TEVA ) blockbuster multiple-sclerosis drug Copaxone, sparking a selloff in Teva as investors worry that generic competition will severely damage the $3.6 billion revenue stream Teva has banked on Copaxone in the last 12 months.
More importantly for Mylan shareholders, the FDA approval rights what's been a very shaky ship in 2017. Before today, Mylan had been staring down a 15% reduction in market value year to date, trailing the rest of the healthcare sector by a massive 35%. Wednesday's double-digit rally in Mylan helps to bridge that gap.
And there are signs of more upside ahead for Mylan from here.  Now the marketing begins.

Traffickers...

Image result for migrants


Over the summer, Italy began funneling cash and logistical support to two major militias in Sabratha after they agreed to stop their involvement in human trafficking and instead act as a police force against it, stopping migrant boats. 

It began when a Libyan militia intercepted a group of human traffickers offshore. That confrontation has spiraled into a weeks-long battle among rival militias for control of a Libyan coastal city that has left dozens dead.
This is a war that started between human traffickers, then snowballed into an ideological and political one.  But voices in Libya decried the deal, fearing that the salaries and supplies would enrich the militias and make them more powerful. The boost to one side threw off the balance of power in Sabratha.
We willingly destroyed the Country of Libya and the outcome is misery all over. 

Friday, October 6, 2017

Concert...

The cartoonist's homepage, knoxnews.com/opinion/charlie-daniel

Strength...

The cartoonist's homepage, indystar.com/opinion/varvel

Super...

The cartoonist's homepage, indystar.com/opinion/varvel

Bubba...

The cartoonist's homepage, knoxnews.com/opinion/charlie-daniel

To B...


Image result for type a personality


Tough time relaxing.
Relaxation isn’t a measurable goal, and it feels like a waste of time

Unrealistic sense of urgency.  “now” is the only time that exists.

Follow a schedule. Our time is carefully orchestrated

Restless. Our motors are always running, so when we have to idle, that excess energy manifests in various nervous habits, such as fidgeting or biting our nails.

To B or not to B...

Restasis...

Image result for st regis mohawk tribe restasis
Allergan transferred the patents for its blockbuster eye drug Restasis to the Saint Regis Mohawk tribe. In return, the tribe licensed the rights back to Allergan, and employed its sovereign immunity to move to dismiss certain challenges by generic drugmakers. Allergan paid the tribe $13.75 million upfront in the arrangement, with the potential for $15 million in annual royalties thereafter.
Claire McCaskill,  "I ask that PhRMA review whether actions to block patent challenges through claims of tribal sovereign immunity align with PhRMA efforts to promote innovation and discourage predatory pricing practices and anticompetitive conduct,"

"This is one of the most brazen and absurd loopholes I've ever seen, and it should be illegal," the senator said in a statement to CNBC.
"Allergan recently completed a Hatch-Waxman trial in a Federal District Court in Texas on the validity of the patents covering Restasis" .

This is only the beginning...